MARKET

TYME

TYME

Tyme Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.120
+0.040
+3.70%
Opening 14:40 09/27 EDT
OPEN
1.100
PREV CLOSE
1.080
HIGH
1.140
LOW
1.080
VOLUME
1.86M
TURNOVER
--
52 WEEK HIGH
4.990
52 WEEK LOW
0.8500
MARKET CAP
192.87M
P/E (TTM)
-6.1708
1D
5D
1M
3M
1Y
5Y
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor
-- HR+/HER2- represents 73% of diagnoses and is the largest subtype of breast cancer(1) -
Business Wire · 7h ago
Tyme Technologies Initiates Dosing in Phase 2 Trial of Oral SM-88 in Metastatic Breast Cancer
MT Newswires · 10h ago
Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?
Every investor in Tyme Technologies, Inc. ( NASDAQ:TYME ) should be aware of the most powerful shareholder groups...
Simply Wall St. · 09/13 18:26
TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
BEDMINSTER, N.J., September 02, 2021--TYME Technologies, Inc. (Nasdaq: TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer...
Business Wire · 09/02 10:50
Tyme Technologies Insider Trades $22.00 thousand in Company Stock
Michael Demurjian, at Tyme Technologies (NASDAQ:TYME), made a large insider sell on August 30, according to a new SEC filing.
Benzinga · 09/01 15:16
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) rose 48.3% to $0.777 in pre-market trading after gaining over 3% on Monday. The company, earlier during the month, reported downbeat quarterly results.
Benzinga · 08/24 11:06
Tyme Technologies Q1 EPS $(0.03) Up From $(0.07) YoY
Tyme Technologies (NASDAQ:TYME) reported quarterly losses of $(0.03) per share. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year.
Benzinga · 08/10 10:46
Earnings Scheduled For August 10, 2021
  Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.
Benzinga · 08/10 08:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TYME. Analyze the recent business situations of Tyme Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TYME stock price target is 9.50 with a high estimate of 9.50 and a low estimate of 9.50.
EPS
Institutional Holdings
Institutions: 102
Institutional Holdings: 17.50M
% Owned: 10.16%
Shares Outstanding: 172.21M
TypeInstitutionsShares
Increased
13
2.26M
New
16
892.89K
Decreased
23
6.90M
Sold Out
20
895.04K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.00%
Pharmaceuticals & Medical Research
-0.73%
Key Executives
Chairman/Chief Scientific Officer/Director
Steve Hoffman
Chief Executive Officer/Director
Richard Cunningham
Chief Financial Officer
Frank Porfido
Executive Vice President
John Rothman
Other
Jonathan Eckard
Other
Jan Van Tornout
Secretary
James Biehl
Independent Director
David Carberry
Independent Director
Donald Degolyer
Independent Director
Douglas Michels
Independent Director
Gerald Sokol
Independent Director
Paul Sturman
Independent Director
Timothy Tyson
No Data
About TYME
TYME Technologies, Inc. is a biotechnology company. The Company is focused on developing cancer metabolism-based therapies (CMBTsTM) for solid tumors and hematologic cancers. The Company’s lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. SM-88 is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis. The Company has multiple cancer metabolism-based assets and other formulations for SM-88 in the pipeline, including injectable, intranasal, and transdermal that are expected to be advanced into the clinical setting.

Webull offers kinds of Tyme Technologies Inc stock information, including NASDAQ:TYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYME stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TYME stock methods without spending real money on the virtual paper trading platform.